Colorectal Cancer

The National Colorectal Cancer Roundtable has created a special toolkit to help physicians successfully determine and evaluate family history to detect colorectal cancer at an earlier age.

“Young people, in general, think they are invincible. I certainly did.” Said Stacy Hurt, an early-age onset rectal cancer survivor.

If patients with colon cancer follow the previously-issued American Cancer Society guidelines on nutrition and physical activity, they can improve outcomes in to survivorship.

With immunotherapy continuing to command headlines in the world of oncology, it’s no surprise that patients with a variety of cancers wonder whether the strategy might help them address and overcome their illnesses.

Funded posthumously by a "Jeopardy!" winner, an immunotherapy research project is under way.

The combination induced a 31 percent disease control rate (DCR) in patients with heavily-pretreated metastatic colorectal cancer (mCRC).

The understanding of genetic mutations, like tumors that are microsatellite instability-high (MSI-H), and the therapies that go along with them is transforming the world of colorectal cancer, according to John Marshall, M.D.

Immunotherapy may play a growing role in treating gastrointestinal cancers categorized as MSI-high.

Laparoscopy proves safer than open surgery and costs less than robotic resection for colorectal cancer.

Next-generation sequencing could help identify MSI-H status in patients, which could have important implications for treatment plans.

A nasty stomach virus might have saved this survivor from colon cancer.

Colorectal cancer expert John Marshall, M.D., shares his feelings about the month of March, which is Colorectal Cancer Awareness month.

Tony Beasley has spent years in the MLB as a third-base coach for the Texas Rangers. Little did he know his competitive nature and critical thinking would come in to play in his fight against stage 2 colorectal cancer. Since, Beasley has teamed up with Fight CRC as part of their One Million Strong Campaign to help others do one thing: Develop a mentality to fight.

CURE spoke with Scott Paulson, M.D., medical oncologist with Texas Oncology, an affiliate of The US Oncology Network, to break down exactly what MSI-H status is, and the effects it may have on certain malignancies.

The identification of microsatellite status, tumor mutational burden and protein expression in colorectal cancer (CRC) tumors may lead to better outcomes in a subgroup of patients.

Patients with microsatellite instability-high (MSI-H) colorectal cancer may undergo a distinct pattern of clonal evolution, which in turn, would impact the use of targeted and immunologic therapies in these patients, according to study results presented at the 2018 Gastrointestinal Cancer Symposium.

Patients previously treated for DNA mismatch repair (MMR)-deficient/microsatellite instability-high (MSI-H) metastatic colorectal cancer may have a new effective treatment option.

Texas Rangers third-base coach Tony Beasley teams up with Fight CRC, sharing his journey into survivorship and inspiring others in their fight against cancer.

Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.

In recent years, next-generation sequencing has allowed physicians and researchers alike to gather more genetic data for patients with gastrointestinal cancers. And while this kind of profiling continues to advance, so do treatment options for this patient population.

Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.

“The very exciting field of checkpoint inhibitors is still evolving, and we are trying to understand where they fit in the world of CRC therapy,” said McCollum, a hematologist and medical oncologist at Texas Oncology.

A recent study found that the cost to patients with breast, lung and colorectal cancers treated in the hospital outpatient setting was nearly $8,000 more than those treated in the community setting.